Mayne Pharma | MYX - Selling And Administration Expenses

Stock Price
4.56
Daily Change
0.06 1.33%
Monthly
-8.80%
Yearly
-4.60%
Q3 Forecast
5.25

Mayne Pharma reported AUD54.8M in Selling and Administration Expenses for its fiscal semester ending in June of 2024.



Financials
Stock Price AUD
Assets AUD 1.14B
Cash and Equivalent AUD 110.07M
Cost of Sales AUD 43.74M
Current Assets AUD 460.59M
Current Liabilities AUD 313.94M
Debt AUD 38.82M
Dividend Yield 0
EBIT AUD -16.2M
EBITDA AUD -65.76M
Employees 900
EPS Earnings Per Share AUD -0.89
Equity Capital and Reserves AUD 454.19M
Gross Profit on Sales AUD 115.99M
Interest Expense on Debt AUD 1.2M
Loan Capital AUD 31.64M
Market Capitalization AUD 382.83M
Net Income AUD -103.68M
Operating Expenses AUD 103.54M
Operating Profit AUD -3.3M
Ordinary Share Capital AUD 1.22B
Pre-Tax Profit AUD -57.61M
Sales Revenues AUD 195.04M
Selling and Administration Expenses AUD 54.8M
Stock AUD 74.63M
Trade Creditors AUD 20.87M
Trade Debtors AUD 193.22M

Selling And Administration Expenses Change Date
Ansell USD 104.45M 115.95M Jun/2024
Avita Medical AUD 21.23M 2.57M Dec/2024
Cochlear AUD 470M 4.4M Dec/2024
CSL USD 1.18B 201M Dec/2024
Healius AUD 393.4M 378.35M Dec/2024
Integral Diagnostics AUD 169.98M 18.73M Jun/2024
Medical Developments International AUD 12.94M 5.87M Dec/2024
Nanosonics AUD 50.26M 26.17M Dec/2024
Next Science USD 10.91M 995.78K Dec/2024
Polynovo AUD 21.13M 18.27M Jun/2024
Ramsay Health Care AUD 5.29B 3.2M Dec/2024
ResMed USD 265.12M 23.51M Jun/2025
Sigma Healthcare AUD 140.17M 5.4M Jul/2024
Sonic Healthcare AUD 2.52B 2.46B Dec/2024
Telix Pharmaceuticals AUD 55.91M 31.78M Dec/2024